- Lunit SCOPE IO® demonstrates potential to assess immune phenotype as an AI-powered biomarker for predicting efficacy of Nivolumab plus Chemotherapy in advanced gastric cancer, independent of PD-L1 status
SEOUL, South Korea,
Sept. 10, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of a significant study at the European Society for Medical Oncology (ESMO) Congress 2024 in
Barcelona, Spain, from
September 13-17.
Register to read this story and more for free.
Signing up for an account helps us improve your browsing experience.
Continue
OR
See our subscription options.
Already have an account? Log in
here
